Welcome to our dedicated page for Baird Medical news (Ticker: BDMD), a resource for investors and traders seeking the latest updates and insights on Baird Medical stock.
Baird Medical Investment Holdings Ltd. develops and commercializes minimally invasive microwave ablation (MWA) medical devices, with a focus on thyroid-related diseases and other soft tissue conditions. News about BDMD commonly covers sales of MWA needles and microwave therapeutic apparatuses, distributor and direct-customer activity, clinical education for physicians, and the company's geographic expansion beyond Mainland China.
Updates also include regulatory clearances in international markets, U.S. clinical-conference engagement, and product-development work tied to software, AI-assisted planning, and robotic surgical systems. Financial releases discuss revenue mix, gross margin, R&D spending, and the effects of market policy and pricing dynamics on the company's China business.
Baird Medical (NASDAQ: BDMD) participated in and supported the 2024 Guangdong Provincial Parathyroid Disease - Southern Yue Forum in Guangzhou, China. The company, specializing in minimally invasive microwave ablation (MWA) technology, showcased its innovations in endocrine care at the event.
The forum brought together medical experts, researchers, and healthcare professionals to discuss advancements in parathyroid disease diagnosis and treatment. As a sponsor, Baird Medical presented its MWA technology designed for endocrine conditions, engaging with key opinion leaders and fostering collaborations to better understand clinical needs.
Baird Medical (NASDAQ: BDMD) sponsored an advanced Microwave Ablation (MWA) training session in New Orleans, focusing on thyroid treatment. The session was led by Dr. Emad Kandil from Tulane University School of Medicine, with participation from Dr. Salem Noureldine of George Washington University. Dr. Noureldine observed five live MWA cases and practiced advanced techniques.
Dr. Kandil, who has performed over 80 MWA procedures, recently presented at the American Thyroid Association meeting, highlighting MWA's effectiveness compared to Radiofrequency Ablation. The training emphasized MWA's efficiency and patient-centered design, notably the absence of grounding pads. Dr. Noureldine received a Certificate of Completion, preparing him to integrate MWA into clinical practice.
Baird Medical (NASDAQ: BDMD) sponsored and participated in the 2024 Guangdong Thyroid Surgery Committee Annual Meeting in Guangdong, China. The two-day event, hosted by the Guangdong Provincial Hospital of Traditional Chinese Medicine, focused on advancing thyroid disease treatment. Baird Medical showcased its microwave ablation (MWA) technology and engaged with healthcare professionals to discuss innovations in endoscopic and minimally invasive surgery.
Chairwoman Haimei Wu emphasized the meeting's importance as a platform for sharing advancements in thyroid ablation and fostering collaboration among experts. The company utilized the interactive sessions to engage with specialists about current challenges and future directions in thyroid care, reinforcing its commitment to advancing minimally invasive surgery solutions globally.
Baird Medical (NASDAQ: BDMD) recently sponsored an advanced Microwave Ablation (MWA) training session in New Orleans, focusing on thyroid care advancement. Led by Dr. Emad Kandil from Tulane University School of Medicine, the program provided hands-on training to two endocrinologists who observed seven live MWA cases.
Dr. Kandil, who has performed over 80 MWA procedures, recently presented at the American Thyroid Association meeting, highlighting MWA's effectiveness compared to Radiofrequency Ablation. The participating physicians received Certificates of Completion, preparing them to integrate MWA into their clinical practices.
The initiative reflects Baird Medical's commitment to expanding access to minimally invasive therapies through physician education and training partnerships.
Baird Medical Group (NASDAQ: BDMD) held its 2024 Annual Review and 2025 Planning Meeting at Baird Capital Tower in Guangzhou, China. The two-day event included participation in the 7th Thyroid Disease Forum and comprehensive reviews of market performance and future strategies.
Production Manager Le Zhang presented the 2025 production schedule and plans for enhanced after-sales service. The company's leadership discussed strengthening distributor relationships to support global expansion goals. The meeting highlighted Baird Medical's recent NASDAQ listing as a milestone that increased international recognition in the minimally invasive medical technologies sector.
Baird Medical (NASDAQ: BDMD) sponsored and participated in the 2024 7th Thyroid Disease Standardized Diagnosis and Treatment Forum in Guangzhou, China. The company showcased its advanced microwave ablation (MWA) technology for thyroid treatments, which features larger ablation zones and shorter treatment times. The event, hosted by Guangdong Provincial People's Hospital, brought together leading medical experts to discuss standardized treatment protocols for thyroid diseases. Chairwoman Haimei Wu emphasized the company's commitment to advancing solutions for thyroid disease management and improving patient outcomes globally.
Baird Medical (NASDAQ: BDMD) sponsored the Surgery of the Thyroid and Parathyroid Glands Course at Massachusetts General Hospital. The event featured discussions on thyroid and parathyroid surgery advancements, with Dr. Shuhang Xu presenting on microwave ablation (MWA) technology for treating thyroid conditions. The presentation highlighted MWA's benefits, including minimally invasive approach, shorter procedures, and precise ablation capabilities. The course covered upcoming American Thyroid Association guidelines and innovations in thyroid cancer management.
Baird Medical (NASDAQ: BDMD) showcased its microwave ablation technology at the Massachusetts Society of Otolaryngology (MSO) event, highlighting its benefits for minimally invasive, office-based surgical procedures. The technology promises higher precision, reduced procedure time, and improved patient recovery, aligning with current trends in Otolaryngology. Attendees showed strong interest in the technology's potential to enhance patient care outcomes and practice efficiency. Baird Medical reaffirmed its commitment to supporting the Otolaryngology community with advanced tools.
Baird Medical (BDMD) showcased its microwave ablation (MWA) technology at the 2024 American Thyroid Association Annual Meeting, drawing significant international attention. The event featured presentations by notable experts, including Dr. Emad Kandil from Tulane University and Dr. Feng Han from Sun Yat-sen University Cancer Center. Dr. Kandil presented clinical data demonstrating MWA's success in cases where RFA failed, emphasizing its safety and effectiveness for thyroid nodule treatment. Dr. Han shared insights on advanced procedural techniques and energy management based on his extensive experience with MWA procedures. The event concluded with hands-on demonstrations of Baird's technology.
Baird Medical hosted and participated in several key thyroid health events from October 24-27, 2024, fostering international collaboration between U.S. and Chinese experts. The company organized the Sixth Global Thyroid Microwave Ablation Technology Exchange Conference on October 25, focusing on advancements in microwave ablation for benign thyroid nodules. Additionally, Baird participated in the 9th Annual China Thyroid Association Conference, the inaugural Western Thyroid Diagnosis and Endoscopy Training Session, and the 4th Hunan Thyroid and Breast Health Forum, demonstrating its commitment to advancing global thyroid care standards.